NCT02008227 · OUTCOME

Maximum Observed Serum Atezolizumab Concentration (Cmax)

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy · Source last updated 2019-12-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: Microgram per milliliter (mcg/mL)
Interval / dispersion: Standard Deviation
Time frame: Predose (Hr 0), 30 minutes (min) post-infusion (infusion duration: 60 min) on Cycle 1 Day 1 (1 Cycle=21 days)

Analysis population: Pharmacokinetic (PK) evaluable population included participants who received atezolizumab treatment and had at least one measurable PK concentration.

Groups in this outcome

Atezolizumab

Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Atezolizumab	606

Reported measurements

Source class 1

Values in Microgram per milliliter (mcg/mL) · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Atezolizumab	400	127	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
127
value
400

denoms

counts
group Id
OG000
value
606
units
Participants

dispersion Type

Standard Deviation

groups

description
Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.
id
OG000
title
Atezolizumab

param Type

MEAN

population Description

Pharmacokinetic (PK) evaluable population included participants who received atezolizumab treatment and had at least one measurable PK concentration.

reporting Status

POSTED

time Frame

Predose (Hr 0), 30 minutes (min) post-infusion (infusion duration: 60 min) on Cycle 1 Day 1 (1 Cycle=21 days)

title

Maximum Observed Serum Atezolizumab Concentration (Cmax)

type

SECONDARY

unit Of Measure

Microgram per milliliter (mcg/mL)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice